In particular, several checkpoint inhibitors such as anti-PD-L1 (e.g. avelumab), anti-PD-1 (e.g. pembrolizumab, nivolumab), and anti-CTLA-4 (e.g. ipilimumab) have been tested clinically and have shown significant benefits for many cancers. Here, CD274 is linked to cancer.